UPDATE : Tuesday, October 15, 2019
상단여백
Celltrion denies delay in local license application for HIV drug Temixys
The Ministry of Food and Drug Safety and Celltrion said rumors about the dr...
by Lee Hye-seon  |  2019-06-25 10:56
라인
Latecomer experimental drug no better than Dupixent in trial
Pharmaceutical firms have strived to make latecomer drugs to beat Dupixent ...
by Kim Yun-mi  |  2019-06-24 15:49
라인
Daewoong wins new indications for Nabota
Daewoong Pharmaceutical's Nabota, its botulinum toxin (BTX) strain, has...
by Lee Han-soo  |  2019-06-24 14:47
라인
Kang Stem Biotech completes P3 trials for stem cell-based atopy treatment
Kang Stem Biotech has completed the subject evaluation of phase 3 clinical ...
by Lee Han-soo  |  2019-06-24 12:19
라인
Anti-cancer Sutene could cause central nervous system abnormality in fetus
Pfizer Korea’s renal cancer treatments Sutene Cap. (ingredient: sunitinib m...
by Lee Hye-seon  |  2019-06-24 11:35
라인
Boryung calls off ₩83-billion supply contract in Jordan
Boryung Pharmaceutical said that it has canceled its contract to supply 83 ...
by Lee Han-soo  |  2019-06-21 18:00
라인
MSD’s antibiotic Zerbaxa fails to get insurance coverage
MSD Korea’s antibiotic drug Zerbaxa Inj. failed to receive insurance covera...
by Kim Eun-young  |  2019-06-21 14:13
라인
‘Customized strategies needed for fast-changing Chinese drug regulation’
Foreign drugmakers need to make the most of China’s revised drug regulation...
by Jeong Sae-im  |  2019-06-21 14:12
라인
Off-label use of Mabthera Inj. denied
The Health Insurance Review and Assessment Service (HIRA) said it has disap...
by Kim Yun-mi  |  2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’
The Korean Cancer Study Group (KCSG) said Korean institutions and researche...
by Kim Yun-mi  |  2019-06-20 15:04
라인
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis
AbbVie has recently announced the latest results from the phase 3 clinical ...
by Lee Han-soo  |  2019-06-19 16:27
라인
Hanmi launches osteoarthritis injection in US
Hanmi Pharmaceutical has launched Hyalrheuma, an hyaluronic acid (HA)- base...
by Lee Han-soo  |  2019-06-19 14:52
라인
Genexine to merge with Toolgen
Genexine and Toolgen have agreed to merge their businesses and become ToolG...
by Lee Han-soo  |  2019-06-19 14:24
라인
‘Keytruda will become most sold orphan drug worldwide by 2024’
The Korea Health Industry Development Institute (KHIDI) recently forecast t...
by Kim Yun-mi  |  2019-06-19 11:11
라인
ABL Bio releases latest data on Parkinson's disease treatment
ABL Bio said that it has presented its latest research result for ABL301, a...
by Lee Han-soo  |  2019-06-18 17:16
라인
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’
Expectations are rising for Lazertinib, an investigational drug that Yuhan ...
by Jeong Sae-im  |  2019-06-18 14:43
라인
LEO Pharma Korea names new CEO
LEO Pharma Korea said Tuesday it appointed Shin Jung-beom as its new chief ...
by Lee Han-soo  |  2019-06-18 14:36
라인
SK Biopharmaceutical's sleepiness treatment commercially available in US
Jazz Pharmaceuticals, SK Biopharmaceutical's U.S. partner, announced th...
by Lee Han-soo  |  2019-06-18 13:42
라인
Korean biosimilars take on original drugs in Europe
Korean biosimilars are threatening original drugs with improved competitive...
by Jeong Sae-im  |  2019-06-17 15:26
라인
AstraZeneca to invest $630 million in Korean biohealth sector
AstraZeneca said it would invest $630 million into Korea’s biotech and heal...
by Kim Yun-mi  |  2019-06-17 11:33
여백
여백
여백
Back to Top